114.66

0.95% -1.10

After Hours: 115.49 0.83 +0.72%

Charles River Laboratories International Inc (CRL)

Overview News Price History Option Chain Financials Discussions Forecast

Charles River Laboratories International Inc stock is traded at $114.66, with a volume of 1.52M. It is down -0.95% in the last 24 hours and down -28.94% over the past month. Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Previous Close:

$115.76

Open:

$113.85

24h Volume:

1.52M

Relative Volume:

0.98

Market Cap:

$5.63B

Revenue:

$4.06B

Net Income/Loss:

$413.08M

P/E Ratio:

14.31

EPS:

8.01

Net Cash Flow:

$560.48M

1W Performance:

+8.12%

1M Performance:

-28.94%

6M Performance:

-37.04%

1Y Performance:

-49.67%

1-Day Range:

$112.12

$115.25

1-Week Range:

$99.80

$116.06

52-Week Range:

$91.86

$254.15

Charles River Laboratories International Inc Stock (CRL) Company Profile

Name

Charles River Laboratories International Inc

Sector

Healthcare (1176)

Industry

Diagnostics & Research (59)

Phone

781-222-6000

Address

251 BALLARDVALE ST, WILMINGTON, MA

Employee

20,100

Twitter

@criverlabs

Next Earnings Date

2024-11-06

Latest SEC Filings

CRL's Discussions on Twitter

Compare CRL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRL Charles River Laboratories International Inc	114.66	5.63B	4.06B	413.08M	560.48M	8.01
TMO Thermo Fisher Scientific Inc	424.24	159.25B	42.88B	6.34B	7.27B	16.53
DHR Danaher Corp	197.14	132.37B	23.82B	3.77B	4.90B	5.15
IDXX Idexx Laboratories Inc	437.44	32.95B	3.90B	887.87M	798.08M	10.67
A Agilent Technologies Inc	106.28	28.58B	6.53B	1.26B	1.31B	4.35
IQV Iqvia Holdings Inc	150.28	24.90B	15.41B	1.37B	2.11B	7.50

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-21-25	Downgrade	Goldman	Buy → Neutral
Mar-04-25	Upgrade	Citigroup	Sell → Neutral
Mar-03-25	Upgrade	Redburn Atlantic	Sell → Neutral
Jan-22-25	Downgrade	William Blair	Outperform → Mkt Perform
Jan-17-25	Downgrade	UBS	Buy → Neutral
Nov-18-24	Downgrade	CLSA	Hold → Underperform
Nov-07-24	Upgrade	CLSA	Underperform → Hold
Oct-23-24	Initiated	CLSA	Underperform
Oct-14-24	Initiated	Redburn Atlantic	Sell
Oct-07-24	Downgrade	Evercore ISI	Outperform → In-line
Oct-02-24	Downgrade	BofA Securities	Buy → Neutral
Oct-01-24	Downgrade	Citigroup	Neutral → Sell
Aug-08-24	Downgrade	JP Morgan	Overweight → Neutral
Aug-08-24	Downgrade	Robert W. Baird	Outperform → Neutral
Jun-28-24	Downgrade	Argus	Buy → Hold
Jun-07-24	Initiated	Mizuho	Neutral
Jun-06-24	Initiated	Goldman	Buy
Feb-15-24	Downgrade	Guggenheim	Buy → Neutral
Sep-13-23	Initiated	TD Cowen	Market Perform
Jul-10-23	Downgrade	Citigroup	Buy → Neutral
Feb-23-23	Upgrade	Guggenheim	Neutral → Buy
Jan-12-23	Downgrade	Jefferies	Buy → Hold
Sep-30-22	Upgrade	Jefferies	Hold → Buy
Aug-25-22	Initiated	Credit Suisse	Outperform
Aug-04-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-24-22	Initiated	Guggenheim	Neutral
Apr-25-22	Downgrade	Jefferies	Buy → Hold
Apr-07-22	Initiated	Stephens	Overweight
Feb-17-22	Reiterated	BofA Securities	Buy
Feb-17-22	Upgrade	Citigroup	Neutral → Buy
Feb-17-22	Reiterated	Deutsche Bank	Buy
Feb-17-22	Reiterated	Morgan Stanley	Overweight
Feb-17-22	Reiterated	UBS	Buy
Aug-05-21	Resumed	Credit Suisse	Neutral
Dec-16-20	Downgrade	Citigroup	Buy → Neutral
Sep-10-20	Upgrade	Jefferies	Hold → Buy
Jul-01-20	Upgrade	BofA Securities	Neutral → Buy
May-13-20	Upgrade	UBS	Neutral → Buy
Apr-21-20	Downgrade	Jefferies	Buy → Hold
Mar-27-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-02-20	Initiated	Deutsche Bank	Buy
Feb-18-20	Upgrade	Wolfe Research	Peer Perform → Outperform
Jan-10-20	Upgrade	Goldman	Neutral → Buy
Jan-08-20	Initiated	Wells Fargo	Overweight
Jan-07-20	Initiated	Citigroup	Buy
Oct-18-19	Downgrade	BofA/Merrill	Buy → Neutral
Jun-10-19	Initiated	SVB Leerink	Outperform
Apr-30-19	Resumed	Evercore ISI	Outperform
Dec-14-18	Initiated	Deutsche Bank	Buy
Oct-09-18	Initiated	UBS	Neutral
Aug-23-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jul-17-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jun-15-18	Upgrade	KeyBanc Capital Mkts	Sector Weight → Overweight
Feb-14-18	Upgrade	SunTrust	Hold → Buy

View All

Charles River Laboratories International Inc Stock (CRL) Latest News

08:21 AM

Cell and Gene Therapy Manufacturing Quality Control Market - openPR.com

08:21 AM

Apr 24, 2025

Animal Model Market Is Booming Worldwide 2025-2032 | Charles River Laboratories International - openPR.com

Apr 24, 2025

Apr 23, 2025

Mice Model Market Seeking Excellent Growth | Charles River, Taconic Biosciences, The Jackson Laboratory - openPR.com

Apr 23, 2025

Apr 22, 2025

High Content Screening and Imaging Market Set for 8.4% CAGR Through 2029 - GlobeNewswire Inc.

Apr 22, 2025

Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development - Business Wire

Apr 22, 2025

Charles River Laboratories Announces Third-Quarter 2024 Results - ADVFN

Apr 22, 2025

Apr 21, 2025

1,000 monkeys in limbo, some stranded in Frederick, Maryland after shipments from Asia - KBOI

Apr 21, 2025

Jefferies Adjusts Price Target on Charles River Laboratories International to $100 From $169, Maintains Hold Rating - marketscreener.com

Apr 21, 2025

Apr 18, 2025

According to the Latest Report: Dermatology CRO Market - openPR.com

Apr 18, 2025

Apr 17, 2025